Cogent Biosciences, Inc.

NASDAQ:COGT

Biotechnology

Healthcare
$27.81 +2.60%

+$0.88 today

Market cap
$4.84B
Beta
0.35
P/E (TTM)
-6.6
EPS (TTM)
-$5.26
52W Low $6.92High $43.73

Volume 2.71M

Average 2.15M

COGT Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Cogent Biosciences, Inc.NASDAQ: COGT

Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026

Cost of revenue remains negative

Q2 FY2026 cost of revenue was $0, compared with $1.16M a year earlier. Trailing-twelve-month cost of revenue was $2.33M.

Context

  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $583K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$4.62M— YoY
LTMJun 2026
$2.33M+101.6% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
4.62M USD
Year-over-year change
—

Cost of Revenue vs competitors

How COGT compares with its peers on the latest reported figures

  • COGT's LTM Jun 2026 cost of revenue of $2.33M is the 7th highest of the 10 companies compared; the peer median is $4.44M.
  • Its year-over-year change of +101.6% is the 4th highest of 7, against a peer median of +141.7%.
COGT Competitors Peer median
Cost of Revenue for COGT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$429.56M +31.6%+21.6%7.4%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$244.96M +232.7%+29.8%108.7%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$94.76M -56.9%-53.2%13.5%
RCUSArcus Biosciences, Inc.LTM Jun 2026$7M ——6.0%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$4.44M +401.7%—2.0%
KURAKura Oncology, Inc.LTM Mar 2026$3.83M +1795.5%—5.3%
COGTCogent Biosciences, Inc.LTM Jun 2026$2.33M +101.6%——
MAZEMaze Therapeutics, Inc.LTM Mar 2026$1.59M ——8.0%
TNGXTango Therapeutics, Inc.LTM Sep 2026$942K +50.7%——
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 ———
Peer median (excluding COGT) $4.44M+141.7%+21.6%7.4%

Competitors are the stored peer set for COGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00004.62M
Gross Profit0000(4.62M)
Gross Margin—————
Research & Development55.91M121.63M173.76M232.66M269.78M
Selling, General & Admin19.64M26.21M34.38M43.28M63.58M
Operating Expenses75.55M147.84M208.13M275.94M328.74M
Depreciation & Amortization147K5.88M3.59M4.35M4.58M
EBITDA(72.13M)(130.37M)(188.82M)(251.51M)(321.29M)
EBITDA Margin—————
Operating Income(75.55M)(147.84M)(208.13M)(275.94M)(333.36M)
Operating Margin—————
Interest Income467K3.99M13.08M18.09M14.69M
Interest Expense03.99M003.06M
Other Income / Expenses3.28M7.6M15.72M20.08M4.43M
Income Before Tax(72.27M)(140.24M)(192.41M)(255.86M)(328.94M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(72.27M)(140.24M)(192.41M)(255.86M)(328.94M)
Net Margin—————
EPS (Basic)(1.85)(2.26)(2.42)(2.32)(2.04)
EPS (Diluted)(1.85)(2.26)(2.42)(2.32)(2.04)
Weighted Avg Shares38.73M58.74M79.66M110.46M160.98M
Weighted Avg Shares (Diluted)38.73M58.74M79.66M110.46M160.98M

Cogent Biosciences, Inc.

NASDAQ:COGT

Intrinsic Alpha fair value

Locked

Current Price

$27.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.